View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 6, 2021

Merck’s Keytruda boosts recurrence-free survival in melanoma trial

The FDA accepted Merck’s sBLA for Keytruda as adjuvant therapy for melanoma, with target action expected by 4 December 2021.

Merck (MSD) has reported that its Keytruda met the primary goal of recurrence-free survival (RFS) as adjuvant therapy in the Phase III KEYNOTE-716 trial for surgically resected high-risk stage II melanoma patients.

A humanised monoclonal antibody, Keytruda hinders the interaction between programmed death receptor-1 (PD-1) and its ligands, PD-L1 and PD-L2, to trigger T lymphocytes that could impact tumour cells and healthy cells.

The anti-PD-1 treatment boosts the immune system’s ability to find and fight tumour cells.

The randomised, two-part Phase III KEYNOTE-716 trial enrolled a total of 954 subjects aged 12 years and above.

RFS was the trial’s primary goal while secondary goals included distant metastasis-free survival, overall survival, safety and quality of life.

In KEYNOTE-716’s double-blind Part 1, subjects received an intravenous dose of Keytruda 200mg or placebo every three weeks for nearly one year.

Subjects in the open-label Part 2 were given the treatment for nearly two years.

Interim analysis data showed that Keytruda monotherapy provided statistically significant and clinically meaningful RFS improvement versus placebo as adjuvant treatment.

Furthermore, no new safety signals linked to the drug were noted in the trial.

Based on the latest results, the US Food and Drug Administration (FDA) accepted a new supplemental biologics licence application (sBLA) for Keytruda as adjuvant therapy for stage IIB or IIC melanoma after full resection in patients aged 12 years and above.

The application also received FDA priority review with a decision anticipated by 4 December 2021.

Merck Research Laboratories global clinical development senior vice-president and head Dr Roy Baynes said: “Many patients with stage II melanoma have a high risk of their cancer returning after surgery.

“This is an important milestone for patients, and we look forward to sharing these results with the medical community as soon as possible.”

Last month, Merck reported that its Keytruda met the primary goal of overall survival in Phase III KEYNOTE-355 trial involving patients with metastatic triple-negative breast cancer.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy